BACKGROUND AND OBJECTIVES: The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. DATA SOURCES AND METHODS: Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. RESULTS: Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. INTERPRETATION AND CONCLUSIONS: The present know- ledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.
BACKGROUND AND OBJECTIVES: The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. DATA SOURCES AND METHODS: Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. RESULTS: Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. INTERPRETATION AND CONCLUSIONS: The present know- ledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.
Authors: Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi Journal: JCI Insight Date: 2016-04-07
Authors: Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi Journal: J Immunol Date: 2015-07-01 Impact factor: 5.422
Authors: Chang Ha Kim; Hoon Jai Chun; Tae Hyung Kim; Wonho Jung; Sunwon Kim; Jong Jin Hyun; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon Tae Jeen; Hong Sik Lee; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu; Insun Kim Journal: Gut Liver Date: 2011-11-21 Impact factor: 4.519
Authors: Piyush Ranjan; Sourabh Dutta; Aanchal Kakkar; Ankur Goyal; Naval K Vikram; Mehar C Sharma; Rita Sood Journal: J Family Med Prim Care Date: 2015 Apr-Jun
Authors: Alina N Khvastunova; Sofya A Kuznetsova; Liubov S Al-Radi; Alexandra V Vylegzhanina; Anna O Zakirova; Olga S Fedyanina; Alexander V Filatov; Ivan A Vorobjev; Fazly Ataullakhanov Journal: Sci Rep Date: 2015-07-27 Impact factor: 4.379